RMGLOBAL HEALTHCARE FUND MANAGEMENT

RMGP BIOPHARMA
INVESTMENT FUND
RMGP Biopharma Investment Fund is focused on early stage innovative therapies in areas of high unmet need. Through its partnership with OrbiMed, Johnson & Johnson and Takeda, RMGP provides an opportunity to invest in the cutting-edge portfolio of the FutuRx incubator. The RMGP Biopharma Investment Fund is managed by RM Global Healthcare Fund Management.
FUTURX PLATFORM
FutuRx is a biotechnology incubator based on novel science developed world-wide, with a unique model for transforming breakthrough discoveries into novel medicines.

FOCUS

RMGP Biopharma Investment Management and its partners identified FutuRx’s innovative early-stage biopharma  portfolio as a highly attractive investment opportunity.

PLATFORM

OrbiMed, Johnson & Johnson and Takeda together with the Israel Innovation Authority founded FutuRx, a biotechnology incubator that serves as a launchpad for biopharma startups.

PORTFOLIO

Highly innovative portfolio of novel first-in-class or best-in-class biopharma assets, for the benefit of patients and healthcare providers, being developed in the FutuRx incubator.

Scroll to top